VAXX - Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting | Benzinga
CAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson's disease at the Annual Academy of Neurology (AAN) 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado.
Presentation details are as follows:
Oral Presentation
Session: ES2 - Emerging Science
Title: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson's Disease
Presenter: Jean-Cosme Dodart, Ph.D., CSO at Vaxxinity
Date & Time: April 16, 2024 at 5:54 pm MT
The AAN Annual Meeting is the largest gathering of neurologists and neuroscience professionals and offers top-tier education, the latest in scientific discoveries, and an abundance of opportunities to connect with friends and colleagues from around the globe.
For more information about Vaxxinity, Inc., visit https://vaxxinity.com/ and follow us on social media @vaxxinity.
About Vaxxinity
Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, ...